FDA's Resolution of Ozempic Shortage Sends Hims & Hers Stocks Plummeting
Feb, 22 2025
Hims & Hers Health saw its stock drop by 19% after the FDA announced the resolution of the Ozempic shortage, impacting the company's alternative formulations. With the mandate to stop production of compounded versions, the company is planning to release a generic alternative to stay competitive.
View More